FDA application filed for generic version of OAB agent
Watson Pharmaceuticals, Inc. has filed an abbreviated new drug application with the FDA to market its darifenacin hydrobromide extended-release 7.5-mg and 15-mg product prior to the expiration of a patent owned by Novartis AG.
Watson Pharmaceuticals, Inc. has filed an abbreviated new drug application with the FDA to market its darifenacin hydrobromide extended-release 7.5-mg and 15-mg product prior to the expiration of a patent owned by Novartis AG.
Watson’s darifenacin hydrobromide extended-release product is the generic version of Novartis AG’s Enablex, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Novartis AG filed suit against Watson on April 24, 2009, seeking to prevent Watson from commercializing its products prior to expiration of the Novartis patent. Watson said in a statement that Novartis AG’s suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson’s abbreviated new drug application for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner.
Dr. Chan on prevention, diagnosis, and treatment of kidney stones in pediatric patients
July 26th 2024"Stones that recur in children happen about 40% to 50% of the time. That's why the American Urological Association guidelines recommend doing a complete metabolic evaluation in all children," says Katherine Chan, MD, MPH.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
